Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2008 Sep 19;22(5):321–326. doi: 10.1002/jcla.20249

p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases

Rong‐Hsing Chen 1,2, Chwen‐Tzuei Chang 1, Tzu‐Yuan Wang 1, Wen‐Liang Huang 1, Chang‐Hai Tsai 3,4, Fuu‐Jen Tsai 3,✉
PMCID: PMC6649067  PMID: 18803266

Abstract

p53 protein participates in the processes of apoptosis, which is involved in a number of immunological reactions. In order to test whether the p53 gene could be used as a genetic marker for the prediction of the development of autoimmune thyroid diseases (AITD), we screened, by using polymerase chain reaction (PCR) analysis, for the C (CC_C)/G (CG_C) polymorphism at the p53 codon 72 (Pro 72/Arg 72) to determine the genotypes of 107 Hashimoto's thyroiditis (HT) and 90 Graves' disease (GD) patients, and 105 normal controls. The data demonstrated that, for the genotype analysis, HT patients featured an enhanced numerical ratio for the Arg/Arg homozygous genotype (33.7%) and a diminished ratio for the Arg/Pro heterozygous genotype (41.1%) at the p53 codon 72 than was the case for normal controls (Arg/Arg: 17.1% and Arg/Pro: 61.9%; P=0.005). The odds ratio for the risk of the Arg/Arg genotype's appearance, compared with that of the Arg/Pro and Pro/Pro genotypes combined, for the HT patient group was 2.450 (95% confidence interval: 1.274–4.716). With respect to allelic analysis, we did not observe significant difference in the frequency of appearance of the Arg allelic variant and the Pro allelic variant for the p53 codon 72 when comparing the HT patient group with the control group (P=0.208). On the other hand, GD patients presented no significant difference in distribution for both genotype and allelic frequencies (P=0.344 and 0.245, respectively) when compared with normal controls. In conclusion, HT patients feature a greater ratio of arginine homozygosity at p53 codon 72 than in the case for normal subjects. The p53 codon 72 proline/arginine polymorphism may be a genetic marker to predict the increased susceptibility of development of HT. J. Clin. Lab. Anal. 22:321–326, 2008. © 2008 Wiley‐Liss, Inc.

Keywords: autoimmune thyroid diseases, Graves' disease, Hashimoto's thyroiditis, p53, polymorphism

REFERENCES

  • 1. Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement‐mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J Clin Endicrinol Metab 1993;77:1700–1705. [DOI] [PubMed] [Google Scholar]
  • 2. Kotani T, Aratake Y, Hirai K, Fukazawa N, Sato H, Ohtaki S. Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Autoimmunity 1995;20:231–236. [DOI] [PubMed] [Google Scholar]
  • 3. Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid‐related proteins in serum. Arch Pathol Lab Med 1987;111:1141–1145. [PubMed] [Google Scholar]
  • 4. Woolner LB, McConahey WM, Beahrs OH. Struma lymphomatosa [Hashimoto's thyroiditis] and the related thyroidal disorder. J Clin Endicrinol Metab 1959;19:53–83. [DOI] [PubMed] [Google Scholar]
  • 5. LiVolsi VA. 2000. Pathology In: Breverman LE, Utiger RD, editors. Werner and Ingbar's the Thyroid. Philadelphia: Lippincott Williams & Wilkins, p 488–511. [Google Scholar]
  • 6. Tanimoto C, Hirakawa S, Hawasaki H, Hayakawa N, Ota Z. Apoptosis in thyroid diseases: A histochemical study. Endocr J 1995;42:193–201. [DOI] [PubMed] [Google Scholar]
  • 7. Martin A, Davies TF. T cells and human autoimmune thyroid disease: Emerging data show lack of need to invoke suppressor T‐cell problem. Thyroid 1992;2:47–61. [DOI] [PubMed] [Google Scholar]
  • 8. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225–235. [DOI] [PubMed] [Google Scholar]
  • 9. Karp G. 2002. Cancer In: Karp G, editor. Cell and Molecular Biology: Concepts and Experiments. New York: Wiley, p 671–702. [Google Scholar]
  • 10. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T‐cell suicide mediated by APO‐1/(Fas/CD95). Nature 1995;373:438–441. [DOI] [PubMed] [Google Scholar]
  • 11. Duke RC, Ojcius DM, Young JD. Cell suicide in health and disease. Sci Am 1996;275:80–87. [DOI] [PubMed] [Google Scholar]
  • 12. Chetty R, O'Laery JJ, Biddolph SC, Gatter KC. Immunohistochemical detection of p53 and Bcl‐2 proteins in Hashimoto's thyroiditis and primary thyroid lymphomas. J Clin Pathol 1995;48:239–241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Okayasu I, Osakabe T, Onozawa M, Mikami T, Fujiwara M. p53 and p21 (WAF1) expression in lymphocytic thyroiditis and thyroid tumors. Clin Immunol Immunopathol 1998;88:183–191. [DOI] [PubMed] [Google Scholar]
  • 14. Fenton CL, Patel A, Tuttle RM, Francis GL. Autoantibodies to p53 in sera of patients with autoimmune thyroid disease. Ann Clin Lab Sci 2000;30:179–183. [PubMed] [Google Scholar]
  • 15. Weetman AP. Autoimmune thyroiditis: Predisposition and pathogenesis. Clin Endocrinol (Oxf) 1992;36:307–323. [DOI] [PubMed] [Google Scholar]
  • 16. Yanagawa T, Taniyama M, Enomoto S, Gomi K, Maruyama H, Ban ST. CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid 1997;7:843–846. [DOI] [PubMed] [Google Scholar]
  • 17. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function. Endocr Rev 2003;24:694–717. [DOI] [PubMed] [Google Scholar]
  • 18. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357–365. [DOI] [PubMed] [Google Scholar]
  • 19. Boltze C, Roessner O, Landt E, Szibor B, Peters R, Schneider‐Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151–1154. [PubMed] [Google Scholar]
  • 20. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004;210:151–157. [DOI] [PubMed] [Google Scholar]
  • 21. Storey A, Thomas M, Kalita A, et al. Role of p53 polymorphism in the development human papillomavirus‐associated cancer. Nature 1998;393:229–234. [DOI] [PubMed] [Google Scholar]
  • 22. Zamzami N, Kroemer G. p53 in apoptosis control: An introduction. Biochem Biophys Res Commun 2005;331:685–687. [DOI] [PubMed] [Google Scholar]
  • 23. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999;29:697–702. [DOI] [PubMed] [Google Scholar]
  • 24. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: A rapid mechanism of p53‐mediated apoptosis. Science 1998;282:290–293. [DOI] [PubMed] [Google Scholar]
  • 25. Giordano C, Stassi C, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275:960–963. [DOI] [PubMed] [Google Scholar]
  • 26. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18:4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Karp G. The chemical basis of life In: Karp G, editor. Cell and Molecular Biology: Concepts and Experiments. New York: Wiley, 2002, p 32–82. [Google Scholar]
  • 28. Jeffrey PD, Gorina S, Palvletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 17 angstroms. Science 1995;267:1498–1502. [DOI] [PubMed] [Google Scholar]
  • 29. Lowe SW, Ruley HE, Jacks T, Housman DE. p53‐dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–967. [DOI] [PubMed] [Google Scholar]
  • 30. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African‐Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205–2208. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES